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Abstract 
Background: Pharmacokinetic studies are vital in development and optimization of drugs. While blood samples can 
be collected either in EDTA, heparin or citrate containing tubes for the estimation of drug levels in plasma, EDTA tubes 
are more commonly used. The purpose of this study was to evaluate the effects of anticoagulants on bioanalysis of 
drugs. Six drugs used extensively in cancer therapy were selected. Albino wistar rats (N = 6 per drug) were dosed 
with one of the following drugs intraperitoneally—pemetrexed (50 mg/kg), imatinib (50 mg/kg), erlotinib (25 mg/kg), 
meropenem (60 mg/kg), 6-mercaptopurine (20 mg/kg) and voriconazole (6 mg/kg). Blood samples were collected 
2 h after dosing (1 h in 6-mercaptopurine group due to short half-life) by terminal bleeding from the retro-orbital 
plexus. Blood was collected in each of Disodium ETDA, heparin, trisodium citrate (TSC) and no anticoagulant (plain) 
tubes. Drug levels in these samples were determined by validated HPLC assays. ANOVA with Tukey’s post hoc test was 
performed to identify statistically significant differences in drug concentrations in anticoagulant tubes. p < 0.05 was 
considered statistically significant.
Results: Significant differences in concentration between anticoagulant tubes was observed in case of erlotinib 
(p = 0.013) and meropenem (p = 0.00), while borderline statistical significance for pemetrexed (p = 0.076). TSC tubes 
overestimated erlotinib levels, heparin tubes underestimated meropenem concentrations and EDTA tubes overesti-
mated pemetrexed concentrations.
Conclusions: Careful selection of anti-coagulant is necessary for accurate characterization of pharmacokinetics of 
drugs. Routine use of EDTA tubes may lead to erroneous interpretation of pharmacokinetic data.
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Background
Appropriate selection, sampling and storage of biological 
samples meant for estimation of drug levels is important, 
yet sometimes overlooked in day-to-day practice. Blood 
is one of the most important specimen of clinical inter-
est as it provides unique advantages over other matrices 
in terms of wide variety of measurements possible, the 
vast amount of published data for both ante-mortem 
and postmortem drug level analysis, and the interpretive 
value of the matrix from a pharmacological standpoint. 
Blood samples can be collected in tubes having a wide 
range of options for preservatives, anticoagulants, and 
other additives and subsequently stored at room tem-
perature, refrigerated, or frozen. The purpose obviously 
is to maintain the sample and the drug or its metabolites 
of interest in a state that will not degrade from the time 
of collection to the time of analysis. Needless to say drug 
testing labs have to develop methodologies for sample 
analysis that allows accurate estimation and interpreta-
tion of the data. For instance, interaction between drugs 
and the type of collection tube used is not uncommon 
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and should be accounted for during analytical method 
development (Boeynaems et  al. 2004; Smets et  al. 2004; 
Wang et al. 2006).
Accurate determination of drug levels in human 
blood samples in clinical trials and routine patient care 
is extremely important. For instance, therapeutic drug 
monitoring (TDM) guides further dose selection of a 
drug based on levels achieved at previous doses. If doses 
are modified based on incorrectly reported drug levels, it 
could lead to sub-therapeutic levels or potential toxicity. 
For anticancer drugs and some anti-microbials with nar-
row therapeutic window and high toxicity, appropriate 
determination of analyte is vital for TDM (Chantry et al. 
2014; Marquet and Rousseau 2008; Paci et al. 2014).
Ethylenediaminetertraaceticacid (EDTA), heparin, and 
trisodiumcitrate (TSC) are the commonly used antico-
agulants. However, the effect of anticoagulants on the 
measurement of blood drug levels is not extensively 
reported in literature. We therefore conducted an experi-
ment to investigate the effect of three commonly used 
anticoagulants, EDTA, heparin and citric acid, on plasma 
drug concentration measurements of six drugs com-
monly used drugs in cancer care.
Methods
Animals
Albino wistar rats (weight range 250 ± 20 gm) of either 
sex were used for the study. The experimental room was 
maintained under standard conditions of temperature 
(25 ±  2  °C) and relative humidity (55 ±  10%). Animals 
were subjected to 12:12 h light dark cycle. Animals were 
housed in standard polypropylene cages with wire mesh 
top and husk as bedding and allowed to acclimatize for 
one week before the start of the study. During this period, 
animals were fed with commercially available rodent 
food pellets and water ad libitum. The experimental pro-
tocol was approved by the Institutional Animal Ethics 
Committee (IAEC) of Gahlot Institute of Pharmacy and 
the experiments were carried out in accordance with the 
current guidelines for the care of laboratory animals.
Experimental protocol
Six drugs commonly used in oncology practice i.e., 
6-mercaptopurine (6-MP), meropenem, erlotinib, 
imatinib, voriconazole and pemetrexed were selected. 
Wistar rats (N  =  36) were divided into six groups and 
each group was administered one of the listed drugs 
intraperitoneally at doses of 50  mg/kg for pemetrexed, 
50 mg/kg for Imatinib, 25 mg/kg for erlotinib, 60 mg/kg 
for meropenem, 20 mg/kg of 6-MP and 6 mg/kg for Vori-
conazole. Blood was withdrawn from the retro orbital 
plexus after 2  h. In the case of 6-MP blood sample was 
collected 1 h after dosing owing to its short half-life. The 
dose and time point of collection was chosen based on 
literature evidence and reported half-life of these drugs 
in rats such that the drug concentration would fall within 
the linearity range of our HPLC assays (Pestieau et  al. 
2000; Wang et  al. 2015; Hoshino-Yoshino et  al. 2011; 
Harrison et  al. 1989; Tterlikkis et  al. 1977; Roffey et  al. 
2003). Blood sample from each animal was collected in 
three tubes containing different anticoagulants i.e. hep-
arin, EDTA, TSC, and a fourth collection tube that did 
not contain any anticoagulant (plain tube). After collec-
tion, each collection tube was centrifuged at 3000 RPM 
at room temperature to separate plasma and was further 
analyzed for drug concentrations by HPLC.
Chemicals
Acetonitrile (ACN), Methanol were procured from Sisco 
Research Laboratoty Pvt. Ltd, India. Dithiothreitol (DTT) 
and Perchloric Acid were obtained from Sigma Aldrich, 
USA. Dipotassium phosphate (K2HPO4), Formic acid 
and Orthophosphoric acid were procured from S D Fine-
Chem Limited, India. Voriconazole was a kind gift of 
Pfizer, India. Erlotinib and Imatinib were kind gifts from 
Natco Pharma Limited, India. Pemetrexed was a kind gift 
of Dr. Reddy’s Laboratories. Meropenem and 6-Mercap-
topurine were procured from Sigma Aldrich, USA.
Sample preparation
The methods were developed in-house and validated 
according to the guidelines for validation of bioanalytical 
methods of FDA (Food and Drug Administration 2001). 
Validation was carried out for assay linearity, accuracy, 
precision and lower limit of quantitation (LLOQ). The 
coefficient of variation relative to reanalysis of the same 
sample was under 15% for all quality control samples of 
low, mid and high concentrations in the linearity range 
for all drugs. The following procedures were used for 
extracting drugs from the plasma:
Imatinib
1000 µL of ACN was added to 100 µL of plasma. This was 
vortexed for 5 min and then centrifuged at 15,000 RPM 
for 10 min at room temperature. 900 µL of the resulting 
supernatant was subsequently dried using LV Speed-
ovap® (Takahe Analytical Instruments) for 35  min at 
40  °C. After complete drying, 100  µL of premix (ACN 
80%, Water 20%) was added, vortexed for 5 min, and cen-
trifuged at 15,000 RPM for 10 min. 90 µL of supernatant 
was transferred into autosampler vials and 30  µL was 
injected into the HPLC.
Erlotinib
1000 µL of ACN was added to 100 µL of plasma. This was 
vortexed for 5 min and then centrifuged at 15,000 RPM 
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for 10 min at room temperature. 900 µL of the resulting 
supernatant was subsequently dried using Speedovap® 
for 35  min at 40  °C. After complete drying, 100  µL of 
premix (ACN 75%, Water 25%) was added, vortexed for 
5 min, and centrifuged at 15,000 RPM for 10 min. 90 µL 
of supernatant was transferred into autosampler vials and 
30 µL was injected into the HPLC.
6‑Mercaptopurine
100 µL of plasma was mixed with 50 µL of DTT (75 mg/
mL in water), 25  µL of water and 25  µL of perchloric 
acid. Vortexed for 5 min and subsequently centrifuged at 
15,000 RPM for 10 min at room temperature. 150 µL of 
supernatant was kept in water bath (100 °C) for 45 min, 
after which it was cooled to room temperature and trans-
ferred into autosampler vials and 30 µL was injected into 
the HPLC.
Voriconazole
Briefly, 800 µL of ACN was added to 100 µL of plasma. 
Vortexed for 5 min and subsequently centrifuged at 
15,000  RPM for 10  min at room temperature. 100  µL 
of supernatant was mixed with 100  µL Buffer solution 
(10  mM Ammonium Acetate, 5 pH), followed by vor-
texing for 2 min and then centrifugation at 15,000 RPM 
for 10  min. 100  µL of supernatant was transferred into 
autosampler vials and 50 µL was injected into the HPLC.
Meropenem
Solid Phase extraction was done using SPE cartridges. 
SPE cartridges were washed with 1 mL methanol followed 
by equilibration with 1 mL equilibration buffer (100 mM 
K2HPO4 pH 6.2). Plasma (100 µL) were then loaded into 
the cartridges. Secondary washing was performed with 
500  µL of an equilibration buffer (pH 6.2). The samples 
were then eluted with 500 µL of 100% ACN followed by 
drying the eluent by Speedovap® (40–45  °C). After dry-
ing, sample was reconstituted with premix (100  µL), 
vortexed for 2 min and centrifuged at 12,000 RPM. [Pre-
mix—A:B (5:95) where, A =  ACN +  Methanol (50:50), 
B =  KH2PO4 Buffer pH 6.2]. 90  µL of the sample were 
loaded into HPLC vials and 30 µL was injected into the 
column.
Pemetrexed
Solid phase extraction was done using SPE cartridge. SPE 
cartridges were conditioned with 0.5  mL methanol fol-
lowed by equilibration with 0.5 mL of 100 mM K2HPO4 
(pH 6.2). Samples were then loaded in the cartridges. 
Secondary washing was done with 0.5  mL of 100  mM 
K2HPO4, pH 6.2 followed by 100% ACN (250 µL). Plasma 
(100 µL) was subsequently eluted with 0.5 mL of Formic 
acid: methanol (5:95). These were dried by Speedovap® 
(40 °C) for 40 min. After drying, samples were reconsti-
tuted with 100 µL of 100 mM K2HPO4 (pH 6.2), vortexed 
for 5  min and centrifuged for 10  min at 15,000  RPM. 
90 µL of this supernatant was loaded into HPLC vials and 
30 µL was injected into the column.
HPLC conditions
HPLC analysis was carried out under the conditions 
mentioned in Table  1. HPLC model: Dionex UHPLC 
Ultimate 3000 with diode array detector Dionex Ultimate 
3000 RS was used. Kinetex® (Phenomenex, USA) col-
umns were used in the analysis.
Statistical analysis
All statistical tests were performed using SPSS 20 (IBM). 
The samples collected in plain tubes (without any anti-
coagulant) were considered as control group and the 
concentrations observed in anticoagulant tubes were nor-
malized against this value. We define ‘plain normaliza-
tion’ as ratio of concentration of the drugs in each of the 
anticoagulant tubes with corresponding concentrations 
in plain tubes of the same animal. This normalization was 
carried out in order to eliminate interanimal variability 
in pharmacokinetics, thus making it possible to attrib-
ute differences in plain normalized values between anti-
coagulant groups to the anticoagulant effect. ANOVA, 
with Tukey’s post hoc test was used to compare the plain 
normalized values between the anticoagulant groups. 
A p value of less than 0.05 was considered statistically 
significant.
Results and discussion
Validation parameters including linearity, accuracy, pre-
cision and LLOQ for each analyte is shown in Table  2. 
The concentration of drugs determined using different 
anticoagulants is presented in Fig. 1 (The raw data show-
ing concentration of each drug observed in each animal 
for different anticoagulants may be found in Additional 
file  1). As seen from the figure, we observed significant 
inter-animal variability within the same anticoagulant 
group. The plain normalized ratios are presented in 
Fig.  2, depicting a tighter set of observations by elimi-
nating interanimal variability, and thereby bringing anti-
coagulant effect to the fore as in the case of erlotinib 
and meropenem. ANOVA test revealed statistically sig-
nificant differences in concentration in case of erlotinib 
(p  =  0.013) and meropenem (p  <  0.01) while border-
line statistical significance for pemetrexed (p  =  0.076) 
between various anticoagulants as seen in Fig. 3. Between 
group comparison using Tukey’s post hock test showed 
that heparin tubes significantly underestimated merope-
nem concentrations when compared to EDTA (Tukey, 
p =  0.001) and TSC tubes (Tukey, p =  0.003) (Fig.  3a). 
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The significance of this observation lies in the fact that 
meropenem is a time-dependent antibiotic which exerts 
antibacterial activity more efficiently if the plasma con-
centration is more than the Minimum Inhibitory Con-
centration (MIC) of the targeted strain of bacteria for at 
least 40% of the dosing interval (fT > MIC > 40%) (Dru-
sano 2003). Under such circumstances, using heparin 
tubes for blood collection may grossly underestimate 
the fraction of time above MIC (fT > MIC) resulting in 
unnecessary dose modifications. In case of erlotinib, 
TSC tubes significantly overestimated the concentration 
of the drug in comparison to heparin (Tukey, p = 0.019) 
and EDTA tubes (Tukey, p = 0.028) (Fig. 3b). In case of 
pemetrexed, concentrations in the EDTA tubes tended to 
be higher than heparin tubes but the difference was not 
statistically significant (Tukey, p = 0.069) (Fig. 3c). Anti-
coagulant effect was not observed in the case of voricon-
azole, imatinib and 6-MP.    
Commonly used anticoagulants for blood collection 
include EDTA, heparin and citrate, EDTA being used 
most frequently. However, EDTA is a known chelator 
and hence not used in estimation of metal ions. Cispl-
atin for example, is collected in heparin coated tubes. 
Identification of such interactions is key to minimizing 
influence of any external factors on the analyte concen-
trations. Barring a few examples, mechanisms by which 
anticoagulants affect the measurement of drug concen-
trations is poorly understood. A study similar to ours 
was performed by Chen et al. (2008) with tigecyclin and 
ciprofloxacin in rats, using EDTA and heparin collection 
Fig. 1 Individual plasma concentrations of a erlotinib, b pemetrexed, c voriconazole, d imatinib, e 6-mercaptopurine and f meropenem when col-
lected in heparin coated, EDTA coated and TSC coated tubes
Table 2 Validation parameters of linearity, accuracy, precision and LLOQ for each analyte
CV coefficient of variation, LLOQ lower limit of quantitation
* Range of accuracy and precision values shown for low, medium and high QC samples
Analyte Linearity range (μg/mL) Accuracy* Precision* (CV %) LLOQ (μg/mL)
Erlotinib 0.1–10 95.6–98.7 3.7–10.5 0.1
Pemetrexed 0.1–10 96.2–101.1 2.9–12.1 0.1
Voriconazole 0.25–8 100.4–102.3 6.0–9.7 0.25
Imatinib 0.1–10 103.3–101.7 3.4–5.7 0.1
6MP 0.1–10 102.4–107.4 4.6–6.1 0.1
Meropenem 0.1–10 89.5–97.2 4.3–4.5 0.1
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tubes. They concluded that EDTA might compete with 
tigecyclin and ciprofloxacin for chelating metal ions, 
thereby affecting drug partitioning in the plasma com-
partment leading to inaccurate estimation of drug levels.
Accurate detection of analyte concentrations is one 
of the most important challenges faced in clinical set-
ting. The FDA Guidance to Industry for bioanalytical 
method validation necessitates evaluation of matrix 
effect (including anticoagulants) before the method can 
be adopted for bioanalysis of drugs, however there are 
no guidelines pertaining to how these effects should be 
evaluated Food and Drug Administration (2001). This 
is often overlooked in non-regulatory studies which 
constitute the major segment of published literature, 
thereby perpetuating errors in the estimation of phar-
macokinetic parameters of drugs. Our findings provide 
compelling argument in favor of identifying the compat-
ibility of anticoagulants with the analytes. To the best of 
Fig. 3 Box and whisker plots of plain normalized ratios of a pemetrexed, b meropenem, c erlotinib depicting statistical significance at indicated p 
values
Fig. 2 Individual plain normalized ratios of a erlotinib, b pemetrexed, c voriconazole, d imatinib, e 6-mercaptopurine and f meropenem when col-
lected in heparin coated, EDTA coated and TSC coated tubes
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our knowledge, this is the first study which has system-
atically evaluated anticoagulant effects on the bioanalysis 
of drugs used in cancer care. Since some of these drugs 
are good candidates for pharmacokinetics guided dose 
optimization or TDM (Moriyama et al. 2015; De Keuke-
leire et al. 2016), and there is evidence emerging in case 
of some others (Herviou et al. 2016), the findings of this 
study clearly underscore the importance of choosing the 
right anticoagulant for pharmacokinetic studies and bio-
analysis of TDM samples. The findings are also relevant 
to other fields including forensic medicine where plasma 
drug levels are often analyzed.
The importance of type of anticoagulant coated collec-
tion tube does not only apply for drugs and metabolite 
concentrations, but has to be extended to other biological 
analytes as well. The influence of various anticoagulants in 
biochemical analytes have been substantiated by several 
studies. Heparin has been identified to interfere with esti-
mation of thyroid hormones and albumin levels (Bowen 
and Remaley 2014). Chuang et  al. (1998) described the 
influence of anticoagulants in amino acid analysis. They 
identified that EDTA reacts with ninhydrin reagent used 
in amino acid analysis and produces a ninhydrin positive 
contaminant, which interferes with the analysis. Similarly, 
they suggested that heparin coated tubes may interfere 
with estimation of sulfur containing amino acids due to 
presence of a preservative, sodium metabisulfite. Sutt-
nar et  al. (2001) demonstrated the underestimation of 
malonaldehyde levels (a marker of lipid peroxidation), 
when collected in EDTA tubes. Lykkesfeldt (2012) noted 
that use of EDTA tubes prevented ex  vivo oxidation of 
oxidative stress biomarkers ascorbate and dehydroascor-
bic acid when compared to 5 other anticoagulants. Mohri 
and Rezapoor (2009) also demonstrated the difference in 
estimating routine biochemical parameters using EDTA, 
heparin and citrate tubes. The chelating nature of EDTA 
and its influence on samples collected for blood clotting 
assay and serum electrolytes was shown by Lima-Oliveria 
et al. (2014, 2015). Cross-contamination of heparinized or 
citrated blood with EDTA was shown to adversely affect 
the blood clotting assay and also the electrolyte levels, 
grossly underestimating them. A study by Wiese et  al. 
(1997) recommended the use of EDTA or heparin tubes 
over citrate tubes as they led to lower lactate concentra-
tion measurement in critically ill.
The spectrum of influence of anticoagulants on ana-
lytes is not only limited to interference with their concen-
trations, but also in analyte stability. More often than not, 
blood samples are not processed immediately. Rather, 
they are refrigerated and are then analyzed at a later 
point of time. This was elucidated by Lam et  al. (2004) 
for DNA analysis, wherein they suggested use of EDTA 
as anticoagulant of choice for delayed blood processing.
Some limitations of our study include a small sample 
size leading to lack of statistical power. However, the 
study still manages to establish the proof of concept in 
spite of this limitation. Secondly, we did not use internal 
standards (IS) in our HPLC assays since we did not want 
to confound our observations by introducing another 
factor (the IS) which may, on its own, be influenced by 
the anticoagulant effect. Instead, we relied on robust vali-
dation of the assays as per FDA bioanalytical validation 
guidelines.
Conclusions
To conclude, the choice of anticoagulant influenced the 
estimation of plasma concentration for three out of 6 
drugs studied. Influence of anticoagulants on the estima-
tion of drug levels should be a guiding factor in choosing 
an appropriate anticoagulant for accurate characteriza-
tion of pharmacokinetics of drugs. EDTA as the anticoag-
ulant of choice is questionable and may lead to erroneous 
interpretation of pharmacokinetic data in some cases.
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